Growth Metrics

BeOne Medicines (BEIGF) Return on Capital Employed (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Return on Capital Employed for 10 consecutive years, with 0.07% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed rose 23.0% to 0.07% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.07% through Dec 2025, up 23.0% year-over-year, with the annual reading at 0.09% for FY2025, 24.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.07% at BeOne Medicines, up from 0.04% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.07% in Q4 2025, with the low at 0.38% in Q1 2023.
  • Average Return on Capital Employed over 5 years is 0.21%, with a median of 0.23% recorded in 2024.
  • The sharpest move saw Return on Capital Employed fell -22bps in 2022, then increased 27bps in 2025.
  • Over 5 years, Return on Capital Employed stood at 0.13% in 2021, then tumbled by -171bps to 0.35% in 2022, then rose by 9bps to 0.31% in 2023, then surged by 50bps to 0.16% in 2024, then surged by 147bps to 0.07% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.07%, 0.04%, and 0.03% for Q4 2025, Q3 2025, and Q2 2025 respectively.